Details of the Drug

General Information of Drug (ID: DMN45IC)

Drug Name

AFM13

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Phase 2	[1]
Mycosis fungoides	2B01	Phase 2	[2]
Peripheral T-cell lymphoma	2A90.C	Phase 2	[2]
Lymphoma	2A80-2A86	Phase 1/2	[3]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin gamma Fc receptor IIIA (FCGR3A)	TTIFOC0	FCG3A_HUMAN	Not Available	[4]
Lymphocyte activation antigen CD30 (TNFRSF8)	TT2GM5R	TNR8_HUMAN	Not Available	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02321592) GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04101331) Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Affimed Therapeutics.